Hematology-American Society of Hematology Education Program

Papers
(The median citation count of Hematology-American Society of Hematology Education Program is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?69
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?69
Neurological manifestations of MGUS60
Anticoagulation at the end of life: whether, when, and how to treat41
Your chemo is no good here: management of high-risk MCL40
Hematopoietic cell transplantation for sickle cell disease: updates and future directions39
Diagnosis and therapeutic decision-making for the neutropenic patient36
On the horizon: upcoming new agents for the management of ITP35
Labor and delivery: DIC, HELLP, preeclampsia34
Mastocytosis demystified31
Recognizing, defining, and managing CAR-T hematologic toxicities30
Bispecific antibody therapies30
Inpatient recognition and management of HLH29
Has PD-1 blockade changed the standard of care for cHL?28
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma26
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease25
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma25
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL25
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient24
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors24
Divergent paths: management of early relapsed follicular lymphoma23
Fitness and frailty in myeloma23
MGCS: where do we stand today?23
BV and beyond: how to incorporate novel agents into PTCL management23
How to recognize and manage COVID-19-associated coagulopathy23
New approaches to tackle cytopenic myelofibrosis22
Selecting initial therapy in CLL22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease21
Troubleshooting heparin resistance20
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia20
How to assess hemostasis in patients with severe liver disease20
Increasing access to allogeneic hematopoietic cell transplant: an international perspective20
Optimizing outcomes in secondary AML20
How to diagnose and manage antiphospholipid syndrome19
Running interferon interference in treating PV/ET: meeting unmet needs19
How to manage hemostasis in patients with liver disease during interventions19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?19
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events19
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity18
Incorporating novel agents into frontline treatment of Hodgkin lymphoma18
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?18
Consumptive coagulopathy in the ICU18
Hemophilia gene therapy: ushering in a new treatment paradigm?18
Management of TKI-resistant chronic phase CML17
Hematology 2022—what is complete HLA match in 2022?17
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation17
Demystifying autoimmune HIT: what it is, when to test, and how to treat17
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores17
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies17
How to manage bleeding disorders in aging patients needing surgery16
Management of limited-stage Hodgkin lymphoma16
Management of marginal zone lymphomas16
What to use to treat AML: the role of emerging therapies15
Organ function indications and potential improvements following curative therapy for sickle cell disease14
Atypical CML: diagnosis and treatment14
Approaches to management of HIT in complex scenarios, including cardiac surgery14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment14
Managing therapy-associated neurotoxicity in children with ALL14
Thrombosis questions from the inpatient wards14
Special considerations in GI bleeding in VWD patients14
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy14
Nontransplant treatment approaches for myeloid neoplasm with mutated TP5313
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?13
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products13
Pegylated interferon: the who, why, and how13
Lower risk but high risk13
Transplant in AML with measurable residual disease: proceed or defer?13
Infectious complications and vaccines13
Treatment of VTE in the thrombocytopenic cancer patient13
When does a PNH clone have clinical significance?13
Alloimmunization and hyperhemolysis in sickle cell disease13
CNS prophylaxis in aggressive B-cell lymphoma13
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment13
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?13
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease12
Cytoreduction for ET and PV: who, what, when, and how?12
What is the ideal approach—doublet, triplet, or quadruplet(s)?12
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms12
What makes a pediatric or young adult patient an appropriate transplant candidate?12
Thrombocytopenia in pregnancy12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?12
Clinical manifestations of telomere biology disorders in adults11
Next-generation therapy for lower-risk MDS11
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation11
Ph− ALL: immunotherapy in upfront treatment11
Managing pregnancy in patients with sickle cell disease from a transfusion perspective11
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax11
Thrombocytopenia and liver disease: pathophysiology and periprocedural management10
Sequencing bispecific antibodies and CAR T cells for FL10
Whom should we treat with novel agents? Specific indications for specific and challenging populations10
The role of stem cell transplant (auto and allo) in PTCL and CTCL10
Approach to the patient with suspected hypereosinophilic syndrome10
Managing side effects: guidance for use of immunotherapies in multiple myeloma10
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?10
Novel therapies upon failure of HMA plus venetoclax10
Stem cell transplantation for ALL: you've always got a donor, why not always use it?10
Porphyria cutanea tarda: a unique iron-related disorder10
Frontline treatment in CLL: the case for time-limited treatment10
Should we use bisphosphonates to treat bone complications in sickle cell disease?10
What else do I need to worry about when treating graft-versus-host disease?10
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome9
IV iron formulations and use in adults9
Barriers to accessing cellular therapy for patients receiving care in community practices9
Immunology 101: fundamental immunology for the practicing hematologist9
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders9
In 2022, which is preferred: haploidentical or cord transplant?9
Treatment of older adult or frail patients with multiple myeloma9
von Willebrand disease and heavy menstrual bleeding: when and how to test9
Are transplant indications changing for myelofibrosis?9
Long-term prophylaxis: what are our options and how to define success?9
Warm autoimmune hemolytic anemia and the best treatment strategies9
Diamond-Blackfan anemia9
Clonal hematopoiesis in frequent whole blood donors9
When should we use it? The role of brentuximab vedotin in 20249
The approach of HMA plus VEN with or without BMT for all patients with AML9
Diagnosis and clinical management of enzymopathies8
Management of Fanconi anemia beyond childhood8
Sequencing therapy in relapsed DLBCL8
New definitions for antiphospholipid syndrome: ready for clinical use?8
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease8
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?8
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia8
Novel platelet products including cold-stored platelets8
Psychosocial and financial issues after hematopoietic cell transplantation8
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice8
Heparin-induced thrombocytopenia and cardiovascular surgery7
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing7
Intravenous iron therapy in pediatrics: who should get it and when is the right time?7
Newborn screening initiatives for sickle cell disease in Africa7
Renal manifestations of MGUS7
New investigational combinations for higher-risk MDS7
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts7
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease7
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too7
Multiple myeloma: a paradigm for blending community and academic care7
Amyloid consults do not have to be vexing7
The intersection of sickle cell disease, stigma, and pain in Africa7
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.7
COVID-19 and thrombosis: searching for evidence7
When to consider inherited marrow failure syndromes in adults7
Mitigating and managing infection risk in adults treated with CAR T-cell therapy7
Using disease-modifying therapies in sickle cell disease7
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas7
Risk-stratification in frontline CLL therapy: standard of care7
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations7
Diagnosis and clinical management of red cell membrane disorders7
The first relapse in multiple myeloma: how to pick the next best thing7
Clonal evolution in inherited marrow failure syndromes predicts disease progression7
Novel clinical care models for patients with sickle cell disease7
Sickle cell disease in India: the journey and hope for the future6
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT36
Double-hit lymphoma: optimizing therapy6
Acute lymphoblastic leukemia in young adults: which up-front treatment?6
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma6
Epidemiology and treatment of priapism in sickle cell disease6
Potential and emerging therapeutics for HHT6
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia6
Transplantation in CML in the TKI era: who, when, and how?6
Cryptogenic oozers and bruisers6
Unexplained arterial thrombosis: approach to diagnosis and treatment6
Challenges to successful outcomes in AYAs with ALL and potential solutions6
Maintenance strategies for relapse prevention and treatment6
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation6
Ph+ ALL in 2022: is there an optimal approach?6
Current use of bispecific antibodies to treat multiple myeloma5
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.5
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line5
AL amyloidosis: untangling new therapies5
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding5
Optimal approach to T-cell ALL5
How immunodeficiency can lead to malignancy5
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease5
How to manage ITP with life-threatening bleeding5
High-risk multiple myeloma: how to treat at diagnosis and relapse?5
Late complications and long-term care of adult CAR T-cell patients5
Acute GVHD: think before you treat5
Sex, lies, and iron deficiency: a call to change ferritin reference ranges5
Management of hemolytic transfusion reactions5
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care5
Ph+ ALL: new approaches for upfront therapy5
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.5
Cellular therapy for multiple myeloma: what's now and what's next5
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease5
Dual-targeted regimens for the frontline treatment of CLL5
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally5
Perioperative consultative hematology: can you clear my patient for a procedure?4
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem4
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia4
Platelet components and bacterial contamination: hospital perspective 20224
Incorporating gonadal health counseling into pediatric care of sickle cell patients4
Allogeneic transplantation for advanced acute leukemia4
Current use of CAR T cells to treat multiple myeloma4
Mutational screening to improve the transplantation decision-making process in MDS4
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept4
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies4
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?4
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia4
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome4
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies4
Approaches to optimize outcomes in transplant recipients4
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT4
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy4
Givosiran: a targeted treatment for acute intermittent porphyria4
Modified T cells as therapeutic agents4
Passive immune therapies: another tool against COVID-194
Identifying and treating iron deficiency anemia in pregnancy4
Novel approaches to acute graft-versus-host disease prevention4
Advances in the management of α-thalassemia major: reasons to be optimistic4
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond4
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas4
Pyruvate kinase activators: targeting red cell metabolism in thalassemia4
0.22074484825134